RxDoctor Payments Data

John Meyer, MD

Internal Medicine · Sarasota, FLNPI 1801828041

Payments from drug & device makers

$1,003in general payments, 2019–2025

Across 53 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$127
  • Exact Sciences$103
  • Novartis$79
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$66
  • Antares Pharma, Inc.$60
  • AstraZeneca$53
  • plus $515 from 20 others

What the payments were for

  • Food & beverage$1,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,003 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$555,492
Medicare patients
645
Services billed
8,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$211,814
EliquisApixaban133$159,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$51,464
MounjaroTirzepatide46$48,106
FarxigaDapagliflozin Propanediol23$24,413
JanuviaSitagliptin Phosphate17$21,133
XareltoRivaroxaban15$20,041
JanumetSitagliptin Phos/Metformin Hcl12$13,165
MovantikNaloxegol Oxalate13$10,754
LinzessLinaclotide11$10,608
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen92$4,364
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,938
SynthroidLevothyroxine Sodium62$3,849
Albuterol Sulfate HfaAlbuterol Sulfate174$3,734
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$3,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$127$211,814171 claims
PfizerEliquis$22$159,662133 claims
GSKTrelegy Ellipta$29$51,46458 claims
Lilly USA, LLCMounjaro$46$48,10646 claims
AstraZenecaFarxiga$53$24,41323 claims
Johnson & JohnsonXarelto$12$20,04115 claims
AbbVieLinzess, Synthroid$35$14,45773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →